BMJ. 1996 Dec 7;313(7070):1429-31.
A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial.
Julian DG, Chamberlain DA, Pocock SJ.
Royal Sussex County Hospital, Brighton.
Objective:
To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction.
Design:
A multicentre unblinded randomised clinical trial.
Setting:
38 hospitals in six countries. SUBJECTS: 1036 patients who had been treated with anistreplase for myocardial infarction were randomly assigned to either aspirin (150 mg daily) or anticoagulation (intravenous heparin followed by warfarin or other oral anticoagulant). The trial was stopped earlier than originally intended because of the slowing rate of recruitment. MAIN OUTCOME MEASURE: Cardiac death or recurrent myocardial infarction at 30 days.
Results:
After 30 days cardiac death or reinfarction, occurred in 11.0% (57/517) of the patients treated with anticoagulation and 11.2% (58/519) of the patients treated with aspirin (odds ratio 1.02, 95% confidence interval 0.69 to 1.50, P = 0.92). Corresponding findings at three months were 13.2% (68/517) and 12.1% (63/519) (0.91, 0.63 to 1.32, P = 0.67). Patients receiving anticoagulation were more likely than patients receiving aspirin to have had severe bleeding or a stroke by three months (3.9% v 1.7% (0.44, 0.20 to 0.97, P = 0.04)).
Conclusion:
No evidence of a difference in the incidence of cardiac events was found between the two treatment groups, though the trial is too small to claim treatment e quivalence confidently. A higher incidence of severe bleeding events and strokes was detected in the group receiving anticoagulation, suggesting that aspirin may be the drug of choice for most patients in this context.
Please click on the required question.n.
- 1 What might I need to know about drugs frequently used in gynaecology?
- 2 How do hormone treatments work?
- 3 In what situations may hormone treatments be indicated?
- 4 What are the sources of hormone treatments?
- 5 What determines the effect of a hormone treatment?
- 6 When are hormones used in combination?
- 7 Why do hormone treatments sometimes cause side effects?
- 8 When are oestrogens prescribed?
- 9 What are the possible side effects and risks of oestrogen therapy?
- 10 When are progestogens prescribed?
- 11 What are the possible side effects and risks of progestogen therapy?
- 12 How is the relative potency (strength) of progestogens measured?
- 13 When is danazol prescribed?
- 14 When are androgens prescribed?
- 15 What are the possible side effects of androgens?
- 16 What are gonadotrophin releasing hormone analogues and gonadotrophins?
- 17 When are GnRH analogues prescribed?
- 18 What are anti-hormones.htm">?
- 19 By which routes can drugs be given and why are they chosen?
- 20 Why do I seem to be given a medication with a different name but my doctor says it is the same as before?
- 21 I am worried about the possible side effects of a medication. What should I do?
- 22 How are new treatments developed?
- 23 What is a meta-analysis?
- 24 What is meant by the term evidence based medicine information?
- 25 What is a clinical trial?
- 26 What is a placebo?
- 27 What is meant by relative risk?
- 28 What is informed consent?
- 29 What is the current opinion of the medical profession on alternative or complementary medicine?
- 30 Support Groups.
Thank you for choosing to visit us.
This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London - Specialist Interests - Reproductive Medicine including Infertility, PCOS, PMS, Menopause and HRT.
I do hope that you find the answers to your women's health questions in the patient information and medical advice provided.
